Fourth Ring Pharmaceuticals: Xuanzhu Biotech's Annerlazol Sodium new indication for eradicating Helicobacter pylori completed the Phase III clinical trial with the first patient enrolled.

The announcement released by SiHuan Pharmaceutical Group stated that Xiuzhu Biotechnology Co., Ltd., a non-wholly owned subsidiary company under the group, has successfully completed the enrollment of the first patient in the Phase III clinical study of Anerylazin sodium enteric-coated tablets, an innovative drug independently developed by the company, for the eradication of Helicobacter pylori in the quadruple therapy containing bismuth salts. This marks the official entry into the substantive execution stage of the key registration clinical research.